Nkarta (NKTX) Enterprise Value (2019 - 2026)
Nkarta (NKTX) posted quarterly Enterprise Value of -$230.4 million for Q1 2026, up 13.21% year-over-year from -$203.5 million in Q1 2025, and up 16.6% quarter-over-quarter from -$276.3 million in Q4 2025.
Nkarta (NKTX) Enterprise Value (2019 - 2026) Analysis & Trends
Nkarta's Enterprise Value history runs 8 years deep, the most recent figure standing at -$230.4 million for Q1 2026.
- In Q1 2026, Enterprise Value rose 13.21% year-over-year to -$230.4 million; the TTM figure through Mar 2026 stood at -$230.4 million (up 13.21% YoY), while the FY2025 annual figure was -$276.3 million, down 3.34% from the prior year.
- Enterprise Value for Q1 2026 stood at -$230.4 million, up from -$276.3 million in the prior quarter.
- The five-year high for Enterprise Value was -$217.0 million in Q1 2022, with the low at -$437.4 million in Q1 2024.
- The 5-year median for Enterprise Value is -$282.3 million (2025), against an average of -$303.5 million.
- The sharpest annual moves came in 2022 and 2025: Enterprise Value plunged 52.25% in 2022, then soared 39.3% in 2025.
- Nkarta's Enterprise Value stood at -$352.1 million in 2022, then gained by 29.52% to -$248.2 million in 2023, then slipped by 7.72% to -$267.4 million in 2024, then dropped by 3.34% to -$276.3 million in 2025, then increased by 16.6% to -$230.4 million in 2026.
- Business Quant data shows NKTX's Enterprise Value at -$230.4 million in Q1 2026, -$276.3 million in Q4 2025, and -$282.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.66 Bn | 131.80 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 86.52 Bn | 78.53 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 65.33 Bn | 60.14 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 59.76 Bn | 54.62 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 42.15 Bn | 37.05 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.84 Bn | 28.53 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.23 Bn | 9.84 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.52 Bn | 26.36 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.29 Bn | 26.46 Bn | - | 2.12 Bn |
| 10 | Nkarta | 198.16 Mn | 198.16 Mn | - | -401.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -401.01 Mn |
| Mar 31, 2026 | -230.43 Mn |
| Dec 31, 2025 | -276.28 Mn |
| Sep 30, 2025 | -282.33 Mn |
| Jun 30, 2025 | -289.69 Mn |
| Mar 31, 2025 | -265.51 Mn |
| Dec 31, 2024 | -267.35 Mn |
| Sep 30, 2024 | -283.06 Mn |
| Jun 30, 2024 | -324.82 Mn |
| Mar 31, 2024 | -437.39 Mn |
| Dec 31, 2023 | -248.19 Mn |
| Sep 30, 2023 | -275.61 Mn |
| Jun 30, 2023 | -280.75 Mn |
| Mar 31, 2023 | -323.34 Mn |
| Dec 31, 2022 | -352.14 Mn |
| Sep 30, 2022 | -392.36 Mn |
| Jun 30, 2022 | -412.95 Mn |
| Mar 31, 2022 | -216.96 Mn |
| Dec 31, 2021 | -238.09 Mn |
| Sep 30, 2021 | -257.70 Mn |